Pfizer Has Big Plans for Paxlovid
July 01 2022 - 05:18AM
TipRanks
Pfizer, Inc. (NYSE: PFE) has submitted a New Drug Application (NDA)
to the U.S. Food and Drug Administration (FDA) for the full
approval of Paxlovid, its antiviral pill for Covid-19. The drug
currently has emergency use authorization (EUA) for the treatment
of mild-to-moderate Covid-19. Albert Bourla, the Chairman and CEO
of Pfizer, said, “Data from our clinical development program,
coupled with the more than 1.7 million patients around the world
who have been prescribed our oral treatment to date, reinforce
Paxlovid as an important treatment option for mild-to-moderate
COVID-19 in patients at greater risk of progression to severe
symptoms, regardless of vaccination status.
https://www.tipranks.com/news/pfizer-has-big-plans-for-paxlovid?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Historical Stock Chart
From Jul 2022 to Aug 2022
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2021 to Aug 2022